Medulloblastoma under Siege: Genetic and Molecular Dissection Concerning Recent Advances in Therapeutic Strategies

• Published in: Journal of pediatric neurosciences 2020-07, Vol.15 (3), p.175-182
• Main Authors: Rawal, Zeal D, Upadhyay, Vinal A, Patel, Dipak D, Trivedi, Trupti I
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; Care and treatment; Chemotherapy; Epigenetic inheritance; Health aspects; Medulloblastoma; Mortality; Review; Surgery
• ISSN: 1817-1745; 1998-3948
• DOI: 10.4103/jpn.JPN_166_18

Medulloblastoma (MB) is a devastating illness with unmet therapeutic needs, predominantly cytotoxic and nontargeted approaches. Survivors of MB also suffer from severe treatment-related effects of radiation and cytotoxic chemotherapy keeping mortality rate significant. Recently, four distinct molecular subgroups of MB have been identified (WNT [wingless], SHH [sonic hedgehog], Group 3, and Group 4). Novel subgroup-specific therapies are being explored in the daily treatment of patients as a clinical trial and are an important challenge in the near term for the pediatric neurooncology society. Epigenetic modifiers are also recurrently affected in MB suggesting that epigenetic therapy can be considered in a subset of patients. Moreover, a hint on forefront procedure; tracer of cancer's genetic information entitled "liquid biopsy" in MB is described. This review examines the recent scientific progress in MB research, with a focus on the genes, pathways that drive tumorigenesis and the advances in conventional and targeted therapy. The identification of subgroup-specific, actionable therapeutic targets has the potential to revolutionize therapy for patients with MB and results in significantly enriched overall survival.